Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Ankylosing spondylitis: new treatment modalities.

Jan Brandt1, Helena Marzo-Ortega, Paul Emery

  • 1Rheumatologische Praxisgemeinschaft, Berlin, Germany.

Best Practice & Research. Clinical Rheumatology
|June 17, 2006
PubMed
Summary

Ankylosing spondylitis (AS) treatment has improved with biological agents targeting tumor necrosis factor-alpha. These therapies show short-term efficacy and safety, but long-term disease modification is still under investigation.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pregnancy outcomes in patients with axial spondyloarthritis: a UK-based survey.

Rheumatology advances in practice·2026
Same author

Whole body-MRI identifies widespread, low intensity inflammation in peripheral joints, and axial involvement in a third of patients with early, treatment-naïve, active PsA: data from the GOLMePsA clinical trial.

Rheumatology (Oxford, England)·2026
Same author

Description and therapy of palmoplantar pustular psoriasis under IL-17A or dual IL-17A/F inhibition.

Journal of autoimmunity·2026
Same author

Difficult-to-treat, complex-to-manage, treatment-refractory spondyloarthritis: semantics or substance?

Current opinion in rheumatology·2026
Same author

The Role of Musculoskeletal Ultrasound in Psoriatic Arthritis: From Preclinical Detection to Treatment Monitoring.

Current rheumatology reports·2026
Same author

Two patterns of sacroiliac joint bone marrow oedema are apparent in AxSpA determined by HLA-B27 status, body mass index or psoriasis.

Joint bone spine·2026

Area of Science:

  • Rheumatology
  • Immunology
  • Pharmacology

Background:

  • Ankylosing spondylitis (AS) is a progressive inflammatory disease impacting young adults.
  • AS significantly increases morbidity and mortality, severely affecting quality of life.
  • Traditional treatments for AS often fail to control symptoms or halt disease progression.

Purpose of the Study:

  • To evaluate the efficacy and safety of biological agents in treating ankylosing spondylitis.
  • To assess the impact of novel therapies on the progression of ankylosing spondylitis.
  • To investigate the potential of biological agents as disease-modifying treatments for AS.

Main Methods:

  • Review of current research on biological agents targeting inflammatory cytokines, specifically tumor necrosis factor-alpha.

Related Experiment Videos

  • Analysis of short- and medium-term clinical trial data for efficacy and safety outcomes.
  • Assessment of ongoing research and future trial requirements for long-term data.

    • Main Results:

    • Biological agents blocking tumor necrosis factor-alpha demonstrate significant efficacy in managing AS symptoms.
    • These novel therapies have shown a favorable safety profile in short- and medium-term studies.
    • Current evidence suggests these agents are effective in controlling active disease in AS patients.

    Conclusions:

    • Biological agents represent a significant advancement in managing ankylosing spondylitis.
    • Further long-term studies are necessary to determine if these treatments are true disease modifiers.
    • The advent of biologics has improved the therapeutic landscape for ankylosing spondylitis.